General
Preferred name
PELITINIB
Synonyms
EKB-569 ()
EKB-569, WAY-EKB-569 ()
WAY-EKB 569 ()
Pelitinib (EKB-569) ()
WAY-EKB-569 ()
Pelitinib ()
P&D ID
PD011006
CAS
257933-82-7
105628-07-7
Tags
available
molecular glue
covalent binder
drug candidate
Drug indication
Lymphoma
Neoplasm
Drug Status
investigational
Max Phase
2.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION Pelitinib is an irreversible inhibitor of EGFR and HER2.

SARS-CoV-2: Action as an allosteric inhibitor at the SARS-CoV-2 3CL (main) protease (Mpro) has been reported . The cyanoquinoline moiety of pelitinib interacts with Ser301 of MPro. (GtoPdb)
DESCRIPTION Pelitinib (EKB-569;WAY-EKB 569) is an irreversible inhibitor of EGFR with an IC50 of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC50s of 282, 800, and 1255 nM, respectively.
PRICE 58
DESCRIPTION Syk inhibitor (Tocris Bioactive Compound Library)
DESCRIPTION Pelitinib is a 3-cyanoquinoline pan-ErbB tyrosine kinase inhibitor with potential antineoplastic activity. EKB-569 irreversibly binds covalently to epidermal growth factor receptors (EGFR) ErbB-1, -2 and -4, thereby inhibiting receptor phosphorylation and signal transduction and resulting in apoptosis and suppression of proliferation in tumor cells that overexpress these receptors. (BOC Sciences Bioactive Compounds)
DESCRIPTION Pelitinib is a potent, low molecular weight, selective, and irreversible inhibitor of epidermal growth factor receptor that is being developed as an anticancer agent. (Enamine Bioactive Compounds)
DESCRIPTION Pelitinib (EKB-569) (EKB-569) is an effective irreversible EGFR inhibitor (IC50: 38.5 nM). (TargetMol Bioactive Compound Library)
Cell lines
9
Organisms
3
Compound Sets
25
AdooQ Bioactive Compound Library
A10706
Axon Medchem Screening Library
1665
BOC Sciences Bioactive Compounds
pelitinib-cas-257933-82-7-item-84-64350
Cayman Chemical Bioactives
15627
ChEMBL Drugs
CHEMBL607707
Clinical kinase drugs
CovalentInDB
CI002775
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB05524
DrugMAP
DMIW453
Enamine Bioactive Compounds
EBC-11317
EU-OPENSCREEN Bioactive Compound Library
EOS101538
Guide to Pharmacology
7644
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL607707
LSP-OptimalKinase library (Laboratory of Systems Pharmacology)
CHEMBL607707
MedChem Express Bioactive Compound Library
HY-32718
MolGlueDB
503
Novartis Chemogenetic Library (NIBR MoA Box)
PKIDB
ReFrame library
Selleckchem Bioactive Compound Library
Pelitinib
TargetMol Bioactive Compound Library
T2327
Tocris Bioactive Compound Library
6349
Welcome Trust Cancer Drugs
282
External IDs
30
Properties
(calculated by RDKit )
Molecular Weight
467.15
Hydrogen Bond Acceptors
6
Hydrogen Bond Donors
2
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
3
cLogP
5.1
TPSA
90.28
Fraction CSP3
0.21
Chiral centers
0.0
Largest ring
6.0
QED
0.45
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
EGFR signaling
Angiogenesis
JAK/STAT Signaling
MAPK
Tyrosine Kinase/Adaptors
Protein Tyrosine Kinase/RTK
Target
EGFR
HER2/ErbB2
MEK
Raf
SRC
ErbB inhibitor
EGFR,MEK,Src
ERBB2
MOA
Inhibitor
EGFR (HER1
erbB1) Inhibitors
Inhibitors of Signal Transduction Pathways
EGFR inhibitor
Member status
virtual
Source data